Regular paperEffects of ApoE4 and maternal history of dementia on hippocampal atrophy
Introduction
As the world population continues to age, Alzheimer's disease (AD) is rapidly becoming a major, and increasing, health care concern. If novel successful therapeutic approaches do not become available, the number of patients with AD is expected to rise from 4.5 million in 2000 to 13.2 million in 2050 in the United States alone (Cummings, 2004, Hebert et al., 2003). The annual cost of care for AD patients worldwide is estimated at $83.9 billion (in 1996 US dollars) and will continue to increase with the rising prevalence of AD (Cummings, 2004, Wimo and Winblad, 2001). The predictions of significant limitations in healthcare resources for elderly care in the near future underscore the pressing need for understanding the pathophysiology of AD and more effective therapies.
The rare variants of early-onset familial AD have been attributed to autosomal dominant mutations in the amyloid precursor protein genes, presenilin 1 and presenilin 2 (Bertram and Tanzi, 2008). The genetics of late onset, sporadic AD are much less clear. Family history is the second greatest risk factor for sporadic AD after age (Tanzi and Bertram, 2001). Having a first-degree relative with AD increases one's risk for AD 4–10 fold (Cupples et al., 2004, Green et al., 2002, Mosconi et al., 2009, Silverman et al., 2005) suggesting a significant genetic component to the sporadic form of the disease. The apolipoprotein E4 (APOE4) gene has repeatedly demonstrated a strong association with late onset AD, but its prevalence of 40%–70% in the AD population suggests that additional genetic risk factors will be discovered (Bertram and Tanzi, 2009, Seripa et al., 2009, Slooter et al., 1998). Several genome-wide association studies have reported other candidate AD-associated genes that warrant further exploration (Bertram and Tanzi, 2009, Li et al., 2006, Rogaeva et al., 2007, Sundar et al., 2007). At the same time, epidemiologic studies have suggested that subjects with maternal history of AD have increased risk of developing the disease (Edland et al., 1996, Ehrenkrantz et al., 1999, Green et al., 2002). The Framingham Offspring study reported that middle-aged individuals with AD-affected mothers show deficient neuropsychological test performance compared with those with AD-affected fathers and those lacking parental history of AD (Wolf et al., 2005). Recently Mosconi et al. reported that relative to subjects with no paternal history of AD those with maternal history of AD not only show decreased glucose uptake in AD-vulnerable regions on positron emission tomography (PET) examination cross-sectionally (Mosconi et al., 2007) but also exhibit progressive decline in glucose uptake in these regions over time (Mosconi et al., 2009). In addition, two recent structural MRI studies examined the effect of parental history of dementia on hippocampal and total brain volume (Debette et al., 2009) and gray matter volume (Honea et al., 2010). The larger study (Debette et al., 2009) reported no effect of history of parental dementia on hippocampal and total brain volume at baseline, or on total brain volume and hippocampal atrophy rates, in cognitively normal subjects. No significant associations were detected after stratification for ApoE4 status as well as for maternal/paternal history of dementia. The smaller study (Honea et al., 2010) likewise studied the effect of maternal and paternal history of AD on brain structure in cognitively normal elderly. They found significantly smaller inferior frontal, middle frontal, inferior temporal, and precuneal gray matter volumes, but no effect on hippocampal volume.
Here we wanted to further explore the effect of maternal history of dementia on the hippocampus, an area affected early by AD pathology. We hypothesized that maternal history of dementia would be associated with greater hippocampal atrophy relative to that seen in groups of subjects with paternal or no parental history of dementia.
“MH” denotes maternal history.
“PH” denotes paternal history.
“MH+/PHany” denotes positive maternal history of dementia (including subjects with positive and negative paternal history of dementia).
“MHany/PH+” denotes positive paternal history of dementia (including subjects with positive and negative maternal history of dementia).
“MH−/PHany” denotes negative maternal history of dementia (including subjects with positive and negative paternal history of dementia).
“MHany/PH−” denotes negative paternal history of dementia (including subjects with positive and negative maternal history of dementia).
“MH+/PH+” denotes positive maternal and paternal history of dementia.
“MH+/PH−” denotes positive maternal and negative paternal history of dementia.
“MH−/PH−” denotes no maternal and no paternal history of dementia.
Section snippets
Subjects
The Alzheimer Disease Neuroimaging Intitiative (ADNI) is a large scale multi-site longitudinal study collecting detailed clinical, imaging, and laboratory data from 200 normal control (NC), 400 amnestic mild cognitive impairment (MCI), and 200 AD subjects at multiple time points over a 4-year period (Mueller et al., 2005) (also see http://www.loni.ucla.edu/ADNI and ADNI-info.org). ADNI's goal is to establish risk factors associated with cognitive decline from normal aging to MCI and from MCI to
Results
The mean group demographic characteristics are presented in Table 1. There were statistically significant differences in age and the prevalence of the ApoE4 allele between the groups. There were no differences in sex, race, education, or mean MMSE scores.
Discussion
A recently published positron emission tomography (PET) study demonstrated significant baseline hypometabolism in the posterior association cortices—known to be affected early in AD—in cognitively normal subjects with maternal history of dementia, while such an effect was absent in those with a paternal history of AD (Mosconi et al., 2007). In a follow-up study, the authors demonstrated progressive decline in posterior cortical glucose uptake in those with a maternal history of AD (Mosconi et
Disclosure statement
The authors have no potential financial or personal conflicts of interest including relationships with other people or organizations within 3 years of beginning the work submitted that could inappropriately influence their work.
Acknowledgements
Data used in preparing this article were obtained from the Alzheimer's Disease Neuroimaging Initiative database (www.loni.ucla.edu/ADNI). Many ADNI investigators therefore contributed to the design and implementation of ADNI or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators is available at www.loni.ucla.edu/ADNI/Collaboration/ADNI_Citation.shtml. All data collection was funded by the following ADNI funding sources
References (61)
- et al.
Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment
Neuropsychologia
(2008) - et al.
Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study
Genet. Med
(2004) - et al.
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease
Neurobiol. Aging
(1997) - et al.
Mini-Mental State: a practical method for grading the cogntive state of patients for the clinician
J. Psychiatr. Res
(1975) - et al.
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Lancet Neurol
(2010) - et al.
Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data
Neuroimage
(2006) - et al.
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry
Neuroimage
(2006) Oxidative stress hypothesis in Alzheimer's disease
Free Radic. Biol. Med
(1997)- et al.
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls
Neuroimage
(2008) - et al.
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls
Neuroimage
(2009)